Amended Statement of Ownership (sc 13g/a)
July 05 2022 - 5:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange
Act of 1934
(Amendment No. 4)*
Sierra Oncology, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
82640U404
(CUSIP Number)
July 1, 2022
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
| * | The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page. |
The information required on the
remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
1 |
NAMES
OF REPORTING PERSONS |
|
Vivo
Capital IX, LLC |
|
2 |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ☒ |
(b) ☐ |
3 |
SEC
USE ONLY |
|
4 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
Delaware |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
5 |
SOLE
VOTING POWER |
0
(1) |
6 |
SHARED
VOTING POWER |
0 |
7 |
SOLE
DISPOSITIVE POWER |
0
(1) |
8 |
SHARED
DISPOSITIVE POWER |
0 |
9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0
(1) |
10 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐ |
|
11 |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
0%
(1) |
12 |
TYPE
OF REPORTING PERSON (See Instructions) |
OO |
| (1) | Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (“GSK”), Orikum Acquisition
Inc. (“Merger Sub”) and Sierra Oncology, Inc. (the “Issuer”) (the “Merger Agreement”), Merger Sub
merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the “Merger”).
At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action
on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. Pursuant to the terms of
the Merger Agreement, the Issuer’s outstanding Series A Warrants (the “Series A Warrants”) were treated in accordance
with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter
represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A
Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. |
1 |
NAMES OF REPORTING
PERSONS |
|
Vivo Opportunity, LLC |
|
2 |
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ☒ |
(b) ☐ |
3 |
SEC USE ONLY |
|
4 |
CITIZENSHIP OR
PLACE OF ORGANIZATION |
Delaware |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON
WITH |
5 |
SOLE
VOTING POWER |
0
(1) |
6 |
SHARED VOTING POWER |
0 |
7 |
SOLE DISPOSITIVE POWER |
0
(1) |
8 |
SHARED DISPOSITIVE POWER |
0 |
9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0
(1) |
10 |
CHECK BOX IF
THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐ |
|
11 |
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9) |
0%
(1) |
12 |
TYPE OF REPORTING
PERSON (See Instructions) |
OO |
| (1) | At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action
on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. Pursuant to the terms of
the Merger Agreement, the Issuer’s outstanding Series A Warrants were treated in accordance with their respective terms such that,
at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive
an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under
the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. |
1 |
NAMES OF REPORTING
PERSONS |
|
Vivo Ventures VII, LLC |
|
2 |
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ☒ |
(b) ☐ |
3 |
SEC USE ONLY |
|
4 |
CITIZENSHIP OR
PLACE OF ORGANIZATION |
Delaware |
NUMBER
OF
SHARES BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
5 |
SOLE
VOTING POWER |
0
(1) |
6 |
SHARED VOTING POWER |
0 |
7 |
SOLE DISPOSITIVE POWER |
0
(1) |
8 |
SHARED DISPOSITIVE POWER |
|
9 |
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0
(1) |
10 |
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐ |
|
11 |
PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9) |
0%
(1) |
12 |
TYPE OF REPORTING PERSON (See
Instructions) |
OO |
| (1) | At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action
on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. Pursuant to the terms of
the Merger Agreement, the Issuer’s outstanding Series A Warrants were treated in accordance with their respective terms such that,
at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive
an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under
the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. |
| Item 1. (a) | Name of Issuer: |
Sierra Oncology,
Inc.
| (b) | Address of Issuer’s Principal
Executive Offices: |
1820 Gateway
Drive, Suite 110, San Mateo, CA, 94404
| Item 2. (a) | Name of Person Filing: |
This Amendment
No. 4 to Schedule 13G is filed jointly by Vivo Capital IX, LLC, Vivo Opportunity, LLC and Vivo Ventures VII, LLC.
| (b) | Address of Principal Business Office or, if None, Residence: |
192 Lytton
Avenue, Palo Alto, CA 94301
Vivo Capital
IX, LLC is a Delaware limited liability company.
Vivo Opportunity,
LLC is a Delaware limited liability company.
Vivo Ventures
VII, LLC is a Delaware limited liability company.
| (d) | Title of Class of Securities: |
Common Stock,
par value $0.001 per share
82640U404
| Item 3. | If This Statement is Filed Pursuant to §§
240.13d-1(b), or 240.13d-2(b) or (c),
Check Whether the Person Filing is a: |
| (a) | ☐ |
Broker or dealer registered under Section 15 of the Act. |
| (b) | ☐ |
Bank as defined in Section 3(a)(6) of the Act. |
| (c) | ☐ |
Insurance company as defined in Section 3(a)(19) of the Act. |
| (d) | ☐ |
Investment company registered under Section 8 of the Investment Company Act of 1940. |
| (e) | ☐ |
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
| (f) | ☐ |
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
| (g) | ☐ |
A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G); |
| (h) | ☐ |
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
| (i) | ☐ |
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; |
| (j) | ☐ |
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); |
| (k) | ☐ |
Group, in accordance with § 240.13d-1(b)(l)(ii)(K). |
If filing as a non-U.S. institution in
accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________
Not Applicable.
| (a) | Amount beneficially owned: |
0
share.
0
share.
| (3) | Vivo Ventures
VII, LLC |
0
share.
Vivo
Capital IX, LLC: 0%
Vivo
Opportunity, LLC: 0%
Vivo
Ventures VII, LLC: 0%
| (c) | Number of shares as to
which such person has: |
| (i) | Sole power to vote or to direct the vote: |
Vivo
Capital IX, LLC: 0 share
Vivo
Opportunity, LLC: 0 share
Vivo
Ventures VII, LLC: 0 share
| (ii) | Shared
power to vote or to direct the vote: 0 |
| (iii) | Sole power to dispose or to direct the disposition of: |
Vivo
Capital IX, LLC: 0 share
Vivo
Opportunity, LLC: 0 share
Vivo
Ventures VII, LLC: 0 share
| (iv) | Shared power to dispose of or to direct the disposition of: 0 |
| Item 5. | Ownership
of Five Percent or Less of a Class. |
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than 5 percent of the class of securities, check the following ☒.
| Item 6. | Ownership
of More than Five Percent on Behalf of Another Person. |
Not
Applicable.
| Item 7. | Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the
Parent Holding Company or Control Person. |
Not
Applicable.
| Item 8. | Identification
and Classification of Members of the Group. |
Not
applicable.
| Item 9. | Notice
of Dissolution of Group. |
Not
applicable.
By signing
below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are
not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection
with a nomination under §240.14a11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Vivo Capital IX, LLC |
|
|
|
July 5, 2022 |
|
(Date) |
|
|
|
/s/ Frank Kung |
|
(Signature) |
|
|
|
Managing Member |
|
(Title) |
|
|
|
Vivo Opportunity, LLC |
|
|
|
July 5, 2022 |
|
(Date) |
|
|
|
/s/ Gaurav Aggarwal |
|
(Signature) |
|
|
|
Managing Member |
|
(Title) |
|
|
|
Vivo Ventures VII, LLC |
|
|
|
July 5, 2022 |
|
(Date) |
|
|
|
/s/ Frank Kung |
|
(Signature) |
|
|
|
Managing Member |
|
(Title) |
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Sep 2023 to Sep 2024